Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
about
Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyPrediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studiesEslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.Eslicarbazepine acetate for the treatment of partial epilepsy.Third generation antiepileptic drug monotherapies in adults with epilepsy.EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence.Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.Antiepileptic drugs in development pipeline: A recent update.Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.Population Pharmacokinetic Evaluation and Missed-Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients With Partial-Onset Seizures.
P2860
Q26745780-AB6173E6-83DB-4F39-B2EC-77CA42A9BBB1Q33881389-B2B17C0D-4D63-4018-9A10-ACADCC44FEA6Q35761335-3450A3A4-02B4-4A89-9C0B-AD9B4B5B2252Q36782895-81F47481-BC91-434B-81ED-459DA8D7D978Q37680030-FFA922B8-04B6-4488-9BCE-5D3F654ED5A0Q38800995-220A840D-C494-49B4-AC1A-D888BD7A8389Q38826584-E7A70148-AAE6-46B5-8F2F-73D41849D6FBQ38849966-9CC9AD2B-73A9-4FE1-83CB-6F78CA820A8CQ39116160-B6742F33-115F-41B1-8367-6F950F2D29ADQ39456360-FE36FBD5-88B5-43BA-BEBE-E3D18C7C0D7CQ44168300-27CE5B83-05EC-4AF7-9441-9B3A53C49453Q47235722-C394937F-D503-4EE1-9F91-37B65231C4F3Q47724046-30035E2E-19AE-4321-BE85-72970B8778FCQ49882750-7DAEE961-276A-48C4-B4AE-4094F12FDC28Q50075643-17216462-214C-4190-B0B2-353214337786Q50205952-6719B260-92EF-47E1-9CE9-0A86E75236B3
P2860
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Efficacy and safety of convers ...... rical-control phase III study.
@ast
Efficacy and safety of convers ...... rical-control phase III study.
@en
type
label
Efficacy and safety of convers ...... rical-control phase III study.
@ast
Efficacy and safety of convers ...... rical-control phase III study.
@en
prefLabel
Efficacy and safety of convers ...... rical-control phase III study.
@ast
Efficacy and safety of convers ...... rical-control phase III study.
@en
P2093
P2860
P1433
P1476
Efficacy and safety of convers ...... orical-control phase III study
@en
P2093
David Blum
Hailong Cheng
Mercedes P Jacobson
Perminder Bhatia
Todd Grinnell
study 046 team
P2860
P2888
P356
10.1186/S12883-015-0305-5
P577
2015-03-28T00:00:00Z
P6179
1051996065